Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6328-6333

  Smee, Donald F ^a   Von Itzstein, Mark ^b   Bhatt, Beenu ^b   Tarbet, E Bart ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; N ACETYL 2,3 DEHYDRO 2 DEOXYNEURAMINIC ACID; UNCLASSIFIED DRUG; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VIRUS A H1N1; MOUSE; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED BALB C; N-ACETYLNEURAMINIC ACID; VIRUS REPLICATION; ZANAMIVIR;

EID: 84869204014     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01664-12     Document Type: Article

References (16)

1. Barnard DL. 2009. Animal models for the study of influenza pathogenesis and therapy. Antiviral Res. 82:A110-A122.
2. Ilyushina NA, et al. 2010. Adaptation of pandemic H1N1 influenza viruses in mice. J. Virol. 84:8607-8616.
3. Itoh Y, et al. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:1021-1025.
4. Judd AK, et al. 1997. In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob. Agents Chemother. 41:687-692.
5. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academy Press, Washington, DC.
6. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
7. Ryan DM, Ticehurst J, Dempsey MH, Penn CR. 1994. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N- acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob. Agents Chemother. 38:2270-2275.
8. Sidwell RW, et al. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51:845-851.
9. Sidwell RW, et al. 1998. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res. 37:107-120.
10. Sidwell RW, Smee DF. 2000. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 48:1-16.
11. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. 2009. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob. Agents Chemother. 53:2120-2128.
12. Smee DF, Julander JG, Tarbet EB, Gross M, Nguyen J. 2012. Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents. Antiviral Res. 96:13-20.
13. Southam DS, Dolovich M, O'Byrne PM, Inman MD. 2002. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am. J. Physiol. Lung Cell. Mol. Physiol. 282:L833-L839.
14. Takano K, Jensen KE, Warren J. 1963. Passive interferon protection in mouse influenza. Proc. Soc. Exp. Biol. Med. 114:472-475.
15. Tarbet EB, et al. 2012. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res. 94:103-110.
16. Taylor RM. 1941. Experimental infection with influenza A virus in mice. The increase in intrapulmonary virus after inoculation and the influence of various factors thereon. J. Exp. Med. 73:43-55.